Rarely, our institutions may test for CDKN2A or BAP1 as a single test, particularly if other cancers, such as pancreatic cancer or astrocytoma in the family, strongly suggest CDKN2A is the offending gene. This evidence concerns the gene CDKN2A and pancreatic neoplasm.